July 28th 2025
The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
SC Efgartigimod Shows Noninferiority to IV Formulation in gMG